Sarcoma Clinical Trials

109 recruiting

Sarcoma Trials at a Glance

477 actively recruiting trials for sarcoma are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Phase 2 with 191 trials, with the heaviest enrollment activity in Houston, New York, and Los Angeles. Lead sponsors running sarcoma studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Mayo Clinic.

Treatments under study

About Sarcoma Clinical Trials

Looking for clinical trials for Sarcoma? There are currently 109 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 477 trials

Recruiting

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

LymphomasHIVKaposi's Sarcoma
National Cancer Institute (NCI)1,029 enrolled1 locationNCT00006518
Recruiting
Phase 3

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled206 locationsNCT06568172
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled248 locationsNCT06422806
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric CancerGastric NeoplasmGastrointestinal Stromal Tumor (GIST)+2 more
National Cancer Institute (NCI)400 enrolled1 locationNCT04557969
Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled190 locationsNCT05691478
Recruiting
Phase 1Phase 2

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Kaposi Sarcoma
National Cancer Institute (NCI)111 enrolled1 locationNCT04941274
Recruiting

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

Financial ToxicityBone Sarcomas
M.D. Anderson Cancer Center100 enrolled1 locationNCT07215611
Recruiting
Phase 1

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

Soft Tissue SarcomaMelanoma
University of Florida18 enrolled1 locationNCT05264974
Recruiting
Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Solid TumorLymphomaGIST+5 more
ITM Solucin GmbH20 enrolled5 locationsNCT06441331
Recruiting
Phase 2

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Sarcoma,Soft Tissue
Yonsei University164 enrolled1 locationNCT04605770
Recruiting
Not Applicable

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma (STS)
Shandong Cancer Hospital and Institute106 enrolled1 locationNCT06980259
Recruiting
Phase 1Phase 2

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Relapsed / Refractory Osteosarcoma
Lantheus Medical Imaging55 enrolled2 locationsNCT07357519
Recruiting
Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Phase 1Phase 2

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Kaposi Sarcoma
National Cancer Institute (NCI)80 enrolled1 locationNCT04303117
Recruiting
Phase 2

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI)40 enrolled1 locationNCT06176989
Recruiting
Phase 2

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 1

A Study of CRD3874-SI in People With Solid Tumors

SarcomaMerkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center81 enrolled7 locationsNCT06021626